益佰制药(600594) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥687,874,165.98, representing a decrease of 16.60% compared to the same period last year[3]. - The net profit attributable to shareholders was ¥50,549,194.35, down 28.79% year-on-year[3]. - The basic earnings per share for the period was ¥0.064, reflecting a decline of 28.89% year-on-year[3]. - Net profit for Q1 2022 was ¥49.07 million, a decline of 27.0% from ¥67.13 million in Q1 2021[18]. - Operating profit for Q1 2022 was ¥70.93 million, a decrease of 13.6% compared to ¥82.08 million in Q1 2021[18]. - Total operating revenue for Q1 2022 was ¥687.87 million, a decrease of 16.6% compared to ¥824.81 million in Q1 2021[17]. - Total operating costs for Q1 2022 were ¥623.41 million, down 16.7% from ¥747.88 million in Q1 2021[17]. Cash Flow and Assets - The net cash flow from operating activities decreased significantly by 87.25%, amounting to ¥52,616,988.53, primarily due to reduced collections and discounts[6]. - Cash flow from operating activities for Q1 2022 was ¥52.62 million, down 87.3% from ¥412.83 million in Q1 2021[22]. - Cash flow from investing activities for Q1 2022 was -¥64.08 million, compared to -¥0.17 million in Q1 2021[22]. - Cash flow from financing activities for Q1 2022 was ¥93.17 million, an improvement from -¥24.11 million in Q1 2021[22]. - The beginning balance of cash and cash equivalents was 378.97 million, while the ending balance reached 460.67 million[23]. - Cash and cash equivalents rose to RMB 460,672,126.35, up from RMB 379,628,229.16, indicating an increase of about 21.4%[13]. - Total current assets increased to RMB 1,929,709,096.81 from RMB 1,725,840,439.71 at the end of 2021, reflecting a growth of approximately 11.8%[14]. - The company's total assets reached RMB 5,263,876,579.34, up from RMB 5,073,897,321.50, reflecting a growth of approximately 3.7%[16]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 63,298[8]. - The largest shareholder, Dou Qiling, holds 23.42% of the shares, with 137,988,740 shares pledged[8]. - The company's total equity attributable to shareholders was ¥3,553,794,319.42, an increase of 1.44% from the previous year[4]. - The equity attributable to shareholders increased to RMB 3,553,794,319.42 from RMB 3,503,200,304.50, showing an increase of about 1.4%[16]. Expenses and Liabilities - Research and development expenses for Q1 2022 were ¥20.54 million, a decrease of 28.0% from ¥28.52 million in Q1 2021[17]. - Sales expenses for Q1 2022 were ¥331.70 million, down 23.5% from ¥434.12 million in Q1 2021[17]. - Total liabilities as of March 31, 2022, amounted to RMB 1,652,309,829.62, compared to RMB 1,511,445,364.60 at the end of 2021, marking an increase of about 9.3%[15]. Investments and Projects - Guizhou Yibai Pharmaceutical's subsidiary Yibai Investment acquired 20% equity of Aide Pharmaceutical for RMB 14 million, aiming for 100% ownership after the transaction completion[10]. - The company sold 19.975% equity of Kangde Pharmaceutical for RMB 10,000, with the transaction currently in the process of equity change registration[11]. - The new factory project of Chang'an Pharmaceutical has reached 94% completion, with major equipment currently undergoing debugging[12]. Accounting Standards - The company is not applying the new accounting standards for the year 2022[23].